ROLE OF 'BISPHOSPHONATES' IN PROSTHODONTICS- A REVIEW.

International Journal of Pharmaceutical Science and Health Care Volume 15, Number 5, 2025 Available online on http://www.rspublication.com/ijphc/index.html ISSN 2249 – 5738 DOI: 10.5281/zenodo.17252890 Original Article ©2025 RS Publicaon, rspublica[email protected] 87 ROLE OF ‘BISPHOSPHONATES’ IN PROSTHODONTICSA REVIEW. Dr.B. LakshmanaRao 1 , Dr. PSH Lakshmi Parvathi 2 , Dr.G. Sirisha 3 , Dr. D. Kundanaveni 4 , Dr.K. BhanuPrasad 5 . 1.Prof & HOD, Dept of Prosthodontics, Lenora Institute of Dental Sciences, Rajahmundry, A.P., 2. Sr. Lecturer, Dept of Prosthodontics, Lenora Institute of Dental Sciences, Rajahmundry, A.P., 3. Reader, Dept of Prosthodontics, Lenora Institute of Dental Sciences, Rajahmundry, A.P., 4. Sr. Lecturer, Dept of Prosthodontics, Lenora Institute of Dental Sciences, Rajahmundry, A.P., 5. Sr. Lecturer, Dept of Prosthodontics, Lenora Institute of Dental Sciences, Rajahmundry, A.P. ARTICLE INFO ABSTRACT ©2025 RS Publicaon Paper ID: IJPHC68DD5F67692DF Received: 2025-09-02 Published: 2025-10-02 DOI: https://dx.doi.org /10.5281/zenodo.17 252890 Page No: 87-102 Bisphosphonates (BPs), particularly nitrogen-containing variants (N-BPs) such as zoledronate, alendronate, ibandronate, pamidronate, and risedronate, represent a promising class of bioactive agents for functionalizing implant surface coatings to enhance osseointegration in dental and orthopedic applications. These coatings allow for localized drug delivery. They directly stop osteoclast-mediated bone resorption by breaking the mevalonate pathway and farnesyl pyrophosphate synthase. They also encourage osteoblast proliferation and differentiation by increasing the activity of osteogenic genes (like BMP-2 and Runx2) and pathways like ERK/JNK. Common materials used for sustained release are titanium dioxide nanotubes (TNTs), hydroxyapatite (HA), mesoporous silica, and organic polymers (like chitosan and PLGA). These materials are used in ways like physical adsorption, covalent grafting, or porous carrier encapsulation. Preclinical studies in sheep and ovariectomized rat models show that zoledronate-coated implants have better early mechanical stability (for example, higher removal torque at 10 days) and more bone-to-implant contact than uncoated controls, with no signs of necrosis. Nonetheless, advantages may be transient (declining by 28 days), and systemic BP application is associated with a 49.96% implant failure rate, which can be reduced by local coatings that prevent these risks. Problems include dose-dependent cytotoxicity at high concentrations (>10^{-4} M) and a lack of long-term clinical data. Future directions focus on hybrid multifunctional coatings that combine N-BPs with growth factors or antimicrobials for personalized, 3D-printed implants. This could change the way osteoporotic patients do things. Keywords: Bisphosphonates (BP); Nitrogen-containing bisphosphonates; Implant surface coatings; Osseointegration; Dental implants; Zoledronate; Osteoclast inhibition. Corresponding Author: Dr.B. LakshmanaRao, Mail: kush[email protected] Internaonal Journal of Pharmaceucal Science and Health Care Available online on h p://www.rspublicaon.com/ijphc/index.html ISSN 2249 – 5738 Cite This Paper: Dr. B. LakshmanaRao, Dr. PSH Lakshmi Parvathi, Dr.G. Sirisha, Dr. D. Kundanaveni and Dr.K. BhanuPrasad (2025). " ROLE OF ‘BISPHOSPHONATES’ IN PROSTHODONTICSA REVIEW.". INTERNATIONAL JOURNAL PHARMACEUTICAL SCIENCE AND HEALTH CARE (IJPHC), vol. 15, no. 5, 2025, pp. 87-102. DOI: https://dx.doi.org/10.5281/zenodo.17252890 International Journal of Pharmaceutical Science and Health Care Volume 15, Number 5, 2025 Available online on http://www.rspublication.com/ijphc/index.html ISSN 2249 – 5738 DOI: 10.5281/zenodo.17252890 Original Article ©2025 RS Publicaon, rspublica[email protected] 88 Introduction: Bisphosphonates are a type of antiresorptive drug that is mostly used to treat diseases that cause bone loss, like osteoporosis, Paget's disease, and bone metastases in people with cancer. They work by binding to hydroxyapatite in bone, which stops osteoclast activity and slows down bone resorption and remodeling. This mechanism can be good or bad for dentistry, where healing and remodeling bone are important for many procedures. [1] Bisphosphonates serve two purposes in general dentistry. On the plus side, they have been looked into for use in periodontal therapy, where using them on the skin or in addition to other treatments can make bones more stable, lower probing pocket depths, and make non-surgical treatments like scaling and root planing work better. In orthodontics, they may regulate tooth movement by affecting the rates of bone remodeling. In endodontics, there is evidence of their effect on root canal therapy, possibly prolonging the healing of periapical lesions due to inhibited bone turnover, while also demonstrating potential in the management of specific inflammatory conditions. [1,2] But the main worry in dentistry is the risk of medication-related osteonecrosis of the jaw (MRONJ), which used to be called bisphosphonate-related osteonecrosis of the jaw (BRONJ). This condition involves necrotic bone that is exposed in the maxillofacial region and does not heal for more than eight weeks. It is often caused by invasive dental procedures like tooth extractions, which can greatly increase the risk (5.3–53 times higher in some studies). Risk factors encompass intravenous administration, extended usage (particularly exceeding four years), elevated dosages in oncology patients, and localized conditions such as periodontal disease or infections. In osteoporosis patients, the incidence is low (0.001–0.01%), but in cancer patients, it is higher (0.5–4.6%). Preventive strategies include dental evaluations before treatment, focusing on less invasive treatments (like endodontics instead of extraction), taking antibiotics before surgery, and keeping good oral hygiene to lower the risk of MRONJ by up to 77%. Before invasive procedures in high-risk cases, patients who are already taking bisphosphonates may want to take a break from the drug for 2 to 3 months. [2,3] Role of Bisphosphonates in Prosthodontics In prosthodontics, which is the field of dentistry that deals with restoring and replacing teeth with prosthetics like dentures, implants, and crowns, bisphosphonates can make things harder because they affect how bones heal and integrate. Patients taking bisphosphonates, especially intravenous forms, are more likely to develop MRONJ after dental procedures like getting an implant or having a tooth pulled. This can make the prosthetic results worse. The American College of Prosthodontists says that implants may fail more often because of poor osseointegration. They also say that patients who have taken intravenous bisphosphonates or taken them for a long time (>4 years) should not get implants. Instead, people prefer alternatives like removable prostheses. [4] For patients with active MRONJ, prosthodontic management focuses on non-invasive methods to reduce trauma. This means using heat-polymerized resilient liners in dentures that are at International Journal of Pharmaceutical Science and Health Care Volume 15, Number 5, 2025 Available online on http://www.rspublication.com/ijphc/index.html ISSN 2249 – 5738 DOI: 10.5281/zenodo.17252890 Original Article ©2025 RS Publicaon, rspublica[email protected] 89 least 1.5 to 3 mm thick to spread out pressure evenly and reduce irritation of the mucosa. Impressions should use low-pressure methods, and occlusion should use teeth without cusps to put less stress on weak bone. People who wear dentures and take bisphosphonates have a twofold higher risk of MRONJ, so they need to have their dentures relined often, with smooth edges and relief over sensitive areas like tori or sharp ridges. Every 2 to 3 months, a followup is very important. Patients should take their prostheses off for at least 12 hours a day and let their doctor know right away if they feel any irritation. [4,5] When bisphosphonate-induced osteonecrosis happens, prosthetic rehabilitation can make life better by lowering pain and stopping secondary infections. This is often done with telescopic overdentures or cover plates as temporary solutions until healing allows for permanent treatment. Fixed prostheses are less risky than removable ones because they have supragingival margins that help keep them clean. In general, a multidisciplinary approach that includes evaluations before treatment and assessments of risks and benefits is necessary for safe prosthodontic care for these patients. [6] Uses of Bisphosphonates in Dentistry Bisphosphonates are mainly antiresorptive agents that stop osteoclast activity and bone remodeling. They are used systemically to treat conditions that cause too much bone loss. In dentistry, their uses are largely indirect, as they are prescribed for systemic conditions but impact dental treatment planning and outcomes. They are used to treat or stop osteoporosis (including postmenopausal, male, and glucocorticoid-induced forms), Paget's disease of bone, hypercalcemia linked to cancer, multiple myeloma, and bone metastases from cancers like breast or prostate cancer. Certain dental applications may serve as adjuncts in periodontal therapy to mitigate bone loss, although evidence is scarce. In implant dentistry, bisphosphonates have been explored for coating implants (e.g., with zoledronate, pamidronate, or ibandronate) or topical administration (e.g., clodronate solution) to enhance osseointegration, reduce marginal bone loss, and improve implant survival rates, particularly in patients with compromised bone density. In general, dentists use them to help patients who are already getting treatment so that procedures like extractions, implants, or periodontal surgery go more smoothly. [1,2,4] Applications of Bisphosphonates in Prosthodontics Bisphosphonates are primarily used systemically for bone-related disorders but have specific applications in prosthodontics, focusing on enhancing bone stability and managing complications during prosthetic treatments. In dental implant procedures, topical applications such as bisphosphonate coatings (e.g., zoledronate, pamidronate, or ibandronate) on titanium implants promote osseointegration by inhibiting osteoclast apoptosis and preserving marginal bone, thereby improving implant success rates in patients with compromised bone density, such as those with osteoporosis. Local delivery systems, like alendronate or zoledronate gels, serve as adjuncts to non-surgical periodontal therapy, reducing bone resorption and probing depths, which indirectly supports prosthetic stability by addressing underlying periodontal issues that could affect dentures or fixed prostheses. For removable prostheses and dentures, International Journal of Pharmaceutical Science and Health Care Volume 15, Number 5, 2025 Available online on http://www.rspublication.com/ijphc/index.html ISSN 2249 – 5738 DOI: 10.5281/zenodo.17252890 Original Article ©2025 RS Publicaon, rspublica[email protected] 90 bisphosphonates are applied in managing patients with medication-related osteonecrosis of the jaw (MRONJ), where heat-polymerized resilient liners (1.5–3 mm thick) are used to distribute occlusal forces evenly, minimizing mucosal trauma and aiding in rehabilitation. In cases of established MRONJ, prosthodontic interventions like telescopic overdentures or cover plates provide interim solutions to improve quality of life by reducing pain and preventing infections until definitive treatment is possible. Fixed prostheses may carry lower risks than removable ones, with designs incorporating supragingival margins to facilitate hygiene. Overall, applications emphasize preventive and adaptive strategies to accommodate impaired bone remodeling. [4-6] Indications of Bisphosphonates in Prosthodontics [1,7,8] In prosthodontics, bisphosphonates are used for patients who need to keep their bones strong and are planning to get prosthetic treatments like implants or dentures. Primary indications encompass osteoporosis (postmenopausal, male, or glucocorticoid-induced), Paget's disease, osteogenesis imperfecta, multiple myeloma, hypercalcemia of malignancy, and bone metastases from cancers (e.g., breast, prostate, lung), administered orally (e.g., alendronate, risedronate, ibandronate) or intravenously (e.g., zoledronate, pamidronate, clodronate). In prosthodontics, they are used to help implants osseointegrate in patients who are not at high risk (for example, those who have been taking oral bisphosphonates for less than five years) by increasing bone density and lowering resorption. This is especially true when they are used with minimally invasive techniques and antibiotic prophylaxis. For periodontal management in addition to prosthetics, indications include localized treatments for periodontitis and enhancing bone stability for denture support or implant sites. In cases of MRONJ, the continued use of bisphosphonates requires prosthodontic interventions for non-invasive rehabilitation, such as resilient-lined dentures, to address jaw necrosis while preserving function. A multidisciplinary evaluation is essential, emphasizing conservative methods such as root canal therapy over extractions to maintain bone integrity for prosthetic results. Contraindications of Bisphosphonates in Prosthodontics Although not strictly contraindicated, bisphosphonates present considerable risks in prosthodontics, particularly due to MRONJ, characterized by necrotic bone exposure lasting over eight weeks, frequently induced by invasive procedures. Relative contraindications encompass intravenous administration (e.g., zoledronate, pamidronate), extended usage (>2–4 years), and elevated dosages in oncology patients, where the incidence of MRONJ escalates to 1–10%, rendering dental implants high-risk due to compromised osseointegration and an average failure rate of 49.96% (increased with IV routes and first-generation bisphosphonates such as clodronate). Comorbidities like smoking, diabetes, high blood pressure, bad oral hygiene, periodontitis, using corticosteroids or chemotherapy, and being over 65 years old make implants more likely to fail and MRONJ more likely to happen (e.g., twofold for denture wearers). For removable dentures, contraindications include the risk of mucosal trauma resulting in MRONJ, necessitating alternatives such as fixed prostheses when feasible. Elective invasive procedures (e.g., post-extractive implants, regenerative surgery) are International Journal of Pharmaceutical Science and Health Care Volume 15, Number 5, 2025 Available online on http://www.rspublication.com/ijphc/index.html ISSN 2249 – 5738 DOI: 10.5281/zenodo.17252890 Original Article ©2025 RS Publicaon, rspublica[email protected] 91 contraindicated in high-risk cases without drug holidays (2–6 months pre/post-surgery) or antibiotics (e.g., amoxicillin/clavulanic acid), although evidence for holidays is limited. In established MRONJ, surgical interventions are contraindicated until conservative management (e.g., irrigation, antibiotics) stabilizes the condition. [1,7,8] Applications of Bisphosphonates in Dental Implants Bisphosphonates (BPs) are antiresorptive agents that inhibit osteoclast activity, primarily utilized for the treatment of bone disorders including osteoporosis, Paget's disease, multiple myeloma, hypercalcemia of malignancy, and bone metastases. When it comes to dental implants, they can be used in two ways: systemically, for patients who need implants because of problems with their bones, and locally, as coatings on implant surfaces to improve osseointegration and bone preservation. These applications are meant to make implants more stable and successful, especially in patients with poor bone quality, while also managing risks like medication-related osteonecrosis of the jaw (MRONJ). [6–8] Systemic Applications Oral bisphosphonates (like alendronate, risedronate, ibandronate, or zoledronate) or intravenous bisphosphonates (like pamidronate) are used in patients who are getting dental implants to stop bone loss caused by osteoporosis or cancer-related bone metastases. This use helps keep bones healthy overall, which may help the implant integrate by lowering resorption and raising bone density. There is no absolute contraindication for implant therapy in BP users, and studies have shown that survival rates are similar (e.g., 94.2% at 5 years and 90.1% at 10 years) when protocols such as antibiotic prophylaxis and minimally invasive techniques are used. For example, in people with osteoporosis, BPs may slow down the loss of bone over time, which can help prosthetics work better in the long term. But there are risks, such as a 65.3% higher implant failure rate (odds ratio 1.653) than in people who don't use them. This is mostly because of problems with bone remodeling, less angiogenesis, and MRONJ (especially with intravenous routes and long-term use of more than 5 years). Smoking, diabetes, corticosteroids, and periodontal disease are some of the comorbidities that raise the risks even more. Recommendations stress the importance of evaluating patients before surgery, taking breaks from drugs for high-risk patients (like intravenous drug users), and taking steps to prevent MRONJ, such as improving oral hygiene and finishing extractions before starting BP therapy. [7,8] Local Applications [1,9-11] In the area, BPs are used as coatings on titanium implant surfaces (like zoledronate, pamidronate, ibandronate, or clodronate) or in gel forms (like alendronate) to help osseointegration and protect the bone around the implant. This application stops osteoclasts from dying, improves bone-implant contact, and slows down the loss of marginal bone. It is especially helpful for people with low bone density or periodontal defects. Some of the benefits are better implant stability quotient (ISQ) values, higher removal torque, more new bone formation (seen in 82% of studies), and less bone loss (for example, 0.20 mm vs. 0.70 mm over International Journal of Pharmaceutical Science and Health Care Volume 15, Number 5, 2025 Available online on http://www.rspublication.com/ijphc/index.html ISSN 2249 – 5738 DOI: 10.5281/zenodo.17252890 Original Article ©2025 RS Publicaon, rspublica[email protected] 92 5 years in coated vs. uncoated implants). There have been no serious side effects, like MRONJ, reported with local use, making it a safer option than systemic administration. There are very few risks, and some studies have shown that the results are the same in 18% of cases. This could be because of differences in coating methods or patient factors. It is suggested to use BP coatings to improve osseointegration, especially when combined with other treatments like scaling and root planing. However, more randomized clinical trials are needed to confirm their long-term effectiveness. In general, systemic applications need careful risk assessment, but local BP applications seem to have a lot of promise for improving the results of dental implants. However, more multicentric studies with longer follow-ups are needed. [1,9-11] Mechanism of Action of Bisphosphonates in Implant Surface Coatings Bisphosphonates (BPs) are stable analogs of pyrophosphate that work mostly as antiresorptive agents by stopping osteoclast activity. This lowers bone resorption and encourages bone formation around implants. In the context of implant surface coatings, BPs are added to allow localized delivery, which improves osseointegration and reduces systemic side effects like osteonecrosis. The mechanism has a number of important pathways: Stopping Osteoclast Activity: Nitrogen-containing bisphosphonates (N-BPs), including zoledronate (ZOL), alendronate (ALN), pamidronate (PAM), risedronate (RIS), and ibandronate, inhibit farnesyl pyrophosphate synthase, disrupt protein prenylation, and induce osteoclast apoptosis by targeting the mevalonate pathway. Etidronate and clodronate are two examples of non-N-BPs that are broken down into cytotoxic ATP analogs, which also cause osteoclast apoptosis. This lessens bone resorption by controlling the OPG/RANKL/RANK signaling pathway. Encouragement of Osteoblast and Osteocyte Activity: BPs increase the activity of alkaline phosphatase and upregulate osteogenic genes (like TGF-β1, VEGF, BMP-2, type-I collagen, and osteocalcin) to encourage the growth and differentiation of osteoblasts. They stop osteoblasts and osteocytes from dying by activating the Src and ERK pathways. This helps bones grow and stops cells from dying from glucocorticoids. Consequences for Bone Mesenchymal Stem Cells (BMSCs): BPs promote osteogenic differentiation of BMSCs by activating ERK and JNK pathways, elevating Runx2 expression, and suppressing PPARγ2 activity, while concurrently inhibiting adipogenic differentiation. In general, these actions balance the activity of osteoblasts and osteoclasts, which improves bone-implant contact (BIC), bone volume (BV), and mechanical stability, especially in people with osteoporosis. It is important to use the right amounts of a substance, such as 10^-8 M for proliferation and <10^-7 M for osteogenic effects. Too much (>10^-4 M) can stop cells from working. Research indicates that BP-coated implants elevate resonance frequency values, removal torque, and stimulate new bone formation in 82% of instances, with no significant adverse effects, such as medication-related osteonecrosis of the jaw (MRONJ), documented for local application. [11-14] International Journal of Pharmaceutical Science and Health Care Volume 15, Number 5, 2025 Available online on http://www.rspublication.com/ijphc/index.html ISSN 2249 – 5738 DOI: 10.5281/zenodo.17252890 Original Article ©2025 RS Publicaon, rspublica[email protected] 93 Methods of Coating Implant Surfaces with Bisphosphonates [11-14] The goal of coating methods for BP-loaded implant surfaces is to achieve controlled, localized release that will improve osseointegration. There are three main types of techniques: physical, chemical, and carrier-based. They often use titanium or hydroxyapatite (HA) substrates. Important methods are: Physical Adsorption: BPs stick to surfaces through non-covalent interactions, like dipping, spray coating, or drop casting. Electrostatic adsorption can slow down the release rates of heparinized surfaces. Heparin-grafted implants with ALN or ZOL adsorbed on titanium dioxide nanotubes (TNTs) for sustained release are some examples. Chemical Bonding: BPs stick to calcium phosphate (CaP) or HA coatings using van der Waals forces, which take advantage of their attraction to calcium ions. Plasma spraying and sol-gel methods are two examples of techniques that raise BIC and BV. HA coatings with ZOL or ALN are two examples. Covalent Attachment: Cross-linking agents like EDC/NHS with fibrinogen or amino-silane (APTMS) are used to hold BPs in place so that the bonds are stable. Silane, polyethylene glycol, heparin, dopamine, and chitosan are examples of linkers that make things more stable than physical methods. Fibrinogen films with PAM or ibandronate are two examples. Micro and Nano Structures and Carrier Systems: Mesoporous TiO2 or SiO2 nanotubes are examples of porous materials that have a lot of surface area for loading and allow for controlled release. Biodegradable organic polymers like chitosan, polycaprolactone, and PLGA wrap around BPs. Electrochemical techniques such as anodization or electrophoretic deposition produce TNTs, with their diameter and length controlling the release rate (for instance, a higher aspect ratio slows the release). Biomimetic coatings mix BPs with HA that doesn't have enough calcium. Polyelectrolyte multilayers use electrostatic forces to build up layer by layer. Other methods are ion implantation and matrix-assisted pulsed laser evaporation (MAPLE) for ALN-HA films. These methods make sure that the drug is released over time, and studies have shown that they work better in models of osteoporosis. [11-14] Future Trends in Implant Surface Coatings with Bisphosphonates Future trends in implant surface coatings with bisphosphonates (BPs) are increasingly focused on leveraging nanotechnology, advanced drug delivery systems, and bioactive modifications to enhance osseointegration, particularly in challenging conditions like osteoporosis, while addressing biosafety and infection risks. Key advancements seek to enhance localized BP release to reduce systemic adverse effects, including medication-related osteonecrosis of the jaw (MRONJ), foster bone regeneration, and incorporate multifunctional attributes such as antibacterial efficacy. [12, 14–16] Nanotechnology and Micro/Nano-Structures International Journal of Pharmaceutical Science and Health Care Volume 15, Number 5, 2025 Available online on http://www.rspublication.com/ijphc/index.html ISSN 2249 – 5738 DOI: 10.5281/zenodo.17252890 Original Article ©2025 RS Publicaon, rspublica[email protected] 94 One of the most important trends is using nanotechnology to make micro and nano structures on implant surfaces to control BP release and improve osseointegration. Titanium dioxide nanotubes (TNTs) are becoming an important platform for BPs like zoledronate to stick to. This lets the BPs be released over time in a way that is controlled by the nanotube's diameter and length through anodic oxidation. This method improves the contact between bones and implants in osteoporotic models by stopping osteoclast activity and encouraging osteoblast growth. Another area of research is nano-scale roughening (under 100 nm), which creates surfaces that improve osteoblast behavior and BP absorption. Commercial products like OsseoSpeed and Nanotite are already paving the way for more widespread use. Graphene-based and nanomaterial coatings are also expected to improve, providing high biocompatibility and cell stimulation. However, there are still problems with cost and validation that need to be worked out. Advanced methods for drug delivery and coating Future coatings will focus on stable, controlled BP delivery using new methods to get around problems with dosage and release kinetics. Covalent grafting with linkers like silane, polyethylene glycol, heparin, dopamine, and chitosan makes the system more stable than physical adsorption, which lets for precise release. Layer-by-layer self-assembly with polyelectrolytes and encapsulation in biocompatible materials (e.g., chitosan, gelatin, polycaprolactone, calcium phosphate) enable gradual BP elution, as demonstrated in nanoparticle systems such as CS/HA/miRNA-21. Biomimetic coprecipitation with hydroxyapatite (HA) and plasma spraying are making progress for BP integration, improving mechanical properties and lowering the risk of chipping. Fibrinogen and other intermediate layers between titanium and BPs (like alendronate, pamidronate, and ibandronate) are becoming more popular for better fixation in human bone. Multifunctional Coatings and Combination Therapies Combining BPs with other bioactive agents is a trend that is growing to improve implant success in many ways. Combinations with growth factors (e.g., VEGF, BMP), anabolic drugs (e.g., PTH 1–34), inorganic elements (e.g., strontium, magnesium, silicon), and genes (e.g., cmyb via nanoparticles) seek to modulate the osteoporotic microenvironment, facilitating angiogenesis and osteogenic differentiation. Doped HA coatings with nanoparticles (like SiO2, Ag, and Mg) make bones and blood vessels grow better. Future-focused antibacterial improvements, like adding artificial antimicrobial peptides (like defensins and cathelicidins), will stop peri-implantitis while keeping BP's anti-resorptive benefits. Personalized drugeluting systems that use nano-carriers and biodegradable materials are becoming available for localized delivery. These systems lower the risk of infection and inflammation. Dealing with osteoporosis and biosafety In osteoporosis, BP coatings are increasingly being administered locally to enhance periimplant bone augmentation and responses, with synergistic effects from calcium phosphate nanoparticles. Future strategies encompass the regulation of macrophage phenotypes International Journal of Pharmaceutical Science and Health Care Volume 15, Number 5, 2025 Available online on http://www.rspublication.com/ijphc/index.html ISSN 2249 – 5738 DOI: 10.5281/zenodo.17252890 Original Article ©2025 RS Publicaon, rspublica[email protected] 95 (transitioning from M1 to M2) for the management of inflammation and the inhibition of bacterial biofilms to avert failures. Concerns about biosafety, like finding the right concentrations to avoid cytotoxicity and making sure that degradation products are safe for use in humans, are important for clinical translation. New technologies and areas of research Additive manufacturing (3D printing) for personalized BP-integrated implants is a significant future trend, enabling customized porosity and bioactive integration; however, long-term effects necessitate further investigation. Smart implants that use nanomaterial biosensors to keep an eye on stability and health in real time are new but promising. In general, future plans call for longer clinical trials, better dose optimization, and studies that compare local and systemic delivery to lower the risks of BRONJ and improve outcomes in compromised bone. [12,14-16] Nitrogen-Containing Bisphosphonate Coated Implants Nitrogen-containing bisphosphonate (N-BP) coated implants are specialized dental or orthopedic implants with surfaces functionalized by coatings incorporating N-BPs, a subclass of bisphosphonates characterized by the presence of nitrogen atoms in their chemical structure, which enhances their potency in inhibiting bone resorption compared to non-nitrogencontaining variants. Zoledronate (a third-generation N-BP), alendronate, pamidronate, risedronate, and ibandronate are some of the most common N-BPs used in these coatings. They are often used on titanium-based implants to help deliver drugs to the bone-implant interface. [17,18] The main goal of these coatings is to improve osseointegration, which is the direct structural and functional connection between the implant and living bone. This is especially important for patients with poor bone quality, like those with osteoporosis, because taking bisphosphonates systemically can lead to problems like medication-related osteonecrosis of the jaw. The coatings aim to improve early mechanical stability, increase bone-to-implant contact (BIC), reduce marginal bone loss, and improve long-term implant success rates while minimizing systemic side effects by allowing for controlled, site-specific release of N-BPs. Mechanism of Action: N-BPs in implant coatings mainly work by changing how bones remodel themselves. They stop osteoclast activity by targeting farnesyl pyrophosphate synthase through the mevalonate pathway. This stops protein prenylation, changes the organization of the cytoskeleton, and causes osteoclast apoptosis. This decreases bone resorption by controlling the OPG/RANKL/RANK signaling pathway. At the same time, NBPs increase alkaline phosphatase activity and the expression of osteogenic genes like TGFβ1, VEGF, BMP-2, type-I collagen, and osteocalcin, which encourages the growth and differentiation of osteoblasts. They also stop osteoblasts and osteocytes from dying by turning on the Src and ERK pathways. They also help bone mesenchymal stem cells (BMSCs) become more like bone cells by turning on the ERK and JNK pathways, increasing Runx2 expression, International Journal of Pharmaceutical Science and Health Care Volume 15, Number 5, 2025 Available online on http://www.rspublication.com/ijphc/index.html ISSN 2249 – 5738 DOI: 10.5281/zenodo.17252890 Original Article ©2025 RS Publicaon, rspublica[email protected] 102 18. Zhang J, Bai H, Bai M, Wang X, Li Z, Xue H, Wang J, Cui Y, Wang H, Wang Y, Zhou R, Zhu X, Xu M, Zhao X, Liu H. Bisphosphonate-incorporated coatings for orthopedic implants functionalization. Mater Today Bio. 2023;22:100737. doi:10.1016/j.mtbio.2023.100737 19. Russell RG. Bisphosphonates: mode of action and pharmacology. Pediatrics. 2007;119 Suppl 2:S150-62. doi:10.1542/peds.2006-2023H 20. Russell RG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int. 2008;19(6):733-59. doi:10.1007/s00198-007-0540-8 21. Russell RG, Rogers MJ. Bisphosphonates: from the laboratory to the clinic and back again. Bone. 1999;25(1):97-106. doi:10.1016/s8756-3282(99)00116-7 22. Peter B, Pioletti DP, Laïb S, et al. Calcium phosphate drug delivery system: influence of local zoledronate release on bone implant osteointegration. Bone. 2005;36(1):52-60. doi:10.1016/j.bone.2004.08.010 23. Rogers MJ. New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des. 2003;9(32):2643-58. doi:10.2174/1381612033453640 24. Dunford JE, Thompson K, Coxon FP, et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther. 2001;296(2):23542. 25. Roelofs AJ, Thompson K, Gordon S, Rogers MJ. Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res. 2006;12(20 Pt 2):6222s-6230s. doi:10.1158/1078-0432.CCR-06-0843 26. Luckman SP, Hughes DE, Coxon FP, Graham R, Russell GG, Rogers MJ. Nitrogencontaining bisphosphonates inhibit the mevalonate pathway and prevent posttranslational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res. 1998;13(4):581-9. doi:10.1359/jbmr.1998.13.4.581 27. Wang Y, Wang J, Hao H, et al. Bisphosphonate-incorporated coatings for orthopedic implants functionalization. Mater Today Bio. 2023;22:100742. doi:10.1016/j.mtbio.2023.100742 28. Chrcanovic BR, Albrektsson T, Wennerberg A. Bisphosphonate treatment and dental implants: A systematic review. Clin Implant Dent Relat Res. 2016;18(4):593-624. doi:10.1111/cid.12337 29. Alqhtani NR, Loganathan A, Narayanan S, Alsalleeh F, Weyman K, Jayaraman T. The Future of Dental Implants: A Narrative Review of Trends, Technologies, and Patient Considerations. J Clin Med. 2025;14(16):4750. doi:10.3390/jcm14164750.